The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | BTKis in R/R MCL: overcoming resistance and the potential of combination regimens
Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, comments on the value of BTK inhibitors (BTKis) in treating relapsed/refractory (R/R) mantle cell lymphoma (MCL), highlighting their use as second- or third-line treatment for patients who have failed standard therapy. Prof. Vose notes that non-covalent BTKis are being explored to overcome resistance, and combination regimens with immunotherapies may be the future of R/R MCL treatment. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
BTK inhibitors are very important treatments that we have for our patients with mantle cell lymphoma. And as we understand the biology better, we’re understanding more and more how to use combinations with BTK inhibitors and also how to try to have new medications that overcome some of the resistance mechanisms of BTK inhibitors. So there’s the covalent versus non-covalent BTK, which definitely has some improvements on patients who have failed the standard treatment and is a second-line treatment or third-line treatment...
BTK inhibitors are very important treatments that we have for our patients with mantle cell lymphoma. And as we understand the biology better, we’re understanding more and more how to use combinations with BTK inhibitors and also how to try to have new medications that overcome some of the resistance mechanisms of BTK inhibitors. So there’s the covalent versus non-covalent BTK, which definitely has some improvements on patients who have failed the standard treatment and is a second-line treatment or third-line treatment. The pirtobrutinib, for example, has shown some very good evidence. I think in the future, we’re going to see a lot more combination treatments using BTK inhibitors, especially in relapsed refractory patients to try to overcome those resistance mechanisms, especially in the patients with TP53 abnormalities or other areas where they’re highly resistant to some of our other therapies. Also, combinations with immunotherapy are going to be very important going forward, as well as targeting some of the other pathways in mantle cell lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Novartis: Honoraria; GenMab: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Pfizer: Research Funding.
